Prevention of Cervical Cancer-Reference-Cited by-同舟云学术

Prevention of Cervical Cancer

Published:2019-02 Issue:02 Volume:79 Page:148-159
ISSN:0016-5751
Container-title:Geburtshilfe und Frauenheilkunde
language:de
Short-container-title:Geburtshilfe Frauenheilkd

Author:

Hillemanns Peter¹,Friese Klaus²,Dannecker Christian³,Klug Stefanie⁴,Seifert Ulrike⁵,Iftner Thomas⁶,Hädicke Juliane⁶,Löning Thomas⁷,Horn Lars⁸,Schmidt Dietmar⁹,Ikenberg Hans¹⁰,Steiner Manfred¹¹,Freitag Ulrich¹²,Siebert Uwe¹³¹⁴,Sroczynski Gaby¹³,Sauerbrei Willi¹⁵,Beckmann Matthias¹⁶,Gebhardt Marion¹⁷,Friedrich Michael¹⁸,Münstedt Karsten¹⁹,Schneider Achim²⁰,Kaufmann Andreas²¹,Petry K.²²,Schäfer Axel²³,Pawlita Michael²⁴,Weis Joachim²⁵,Mehnert Anja²⁶,Fehr Mathias²⁷,Grimm Christoph²⁸,Reich Olaf²⁹,Arbyn Marc³⁰,Kleijnen Jos³¹,Wesselmann Simone³²,Nothacker Monika³³,Follmann Markus³⁴,Langer Thomas³⁴,Jentschke Matthias¹

Affiliation:

1. Klinik für Frauenheilkunde und Geburtshilfe, Medizinische Hochschule Hannover, Hannover, Germany

2. Klinik Bad Trissl GmbH, Oberaudorf, Germany

3. Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, München, Germany

4. Lehrstuhl für Epidemiologie, Technische Universität München, München, Germany

5. Tumorepidemiologie, Universitäts KrebsCentrum (UCC), Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany

6. Institut für Medizinische Virologie und Epidemiologie der Viruskrankheiten, Universitätsklinikum Tübingen, Tübingen, Germany

7. Institut für Pathologie, Albertinen-Krankenhaus Hamburg, Hamburg, Germany

8. Institut für Pathologie, Universitätsklinikum Leipzig, Leipzig, Germany

9. Institut für Pathologie, Referenzzentrum für Gynäkopathologie, Mannheim, Germany

10. CytoMol – MVZ für Zytologie und Molekularbiologie, Frankfurt, Germany

11. Facharzt für Frauenheilkunde und Geburtshilfe, Ihringen, Germany

12. Facharzt für Frauenheilkunde und Geburtshilfe, Wismar, Germany

13. Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT – University for Health Sciences, Medical Informatics and Technology, Hall i. T., Austria

14. Division of Health Technology Assessment and Bioinformatics, ONCOTYROL – Center for Personalized Cancer Medicine, Innsbruck, Austria

15. Institut für Med. Biometrie und Statistik (IMBI), Universitätsklinikum Freiburg, Freiburg, Germany

16. Frauenklinik, Universitätsklinikum Erlangen, Erlangen, Germany

17. Frauenselbsthilfe nach Krebs, Forchheim, Germany

18. Klinik für Frauenheilkunde und Geburtshilfe, Helios Klinikum Krefeld, Krefeld, Germany

19. Frauenklinik, Ortenau Klinikum Offenburg-Gengenbach, Offenburg, Germany

20. Medizinisches Versorgungszentrum im Fürstenberg-Karree, Berlin, Germany

21. Klinik für Gynäkologie, Campus Benjamin Franklin, Charité – Universitätsmedizin Berlin, Berlin, Germany

22. Frauenklinik, Klinikum Wolfsburg, Wolfsburg, Germany

23. Facharzt für Frauenheilkunde und Geburtshilfe, Berlin, Germany

24. Deutsches Krebsforschungszentrum, Heidelberg, Germany

25. Klinik für Tumorbiologie, Klinik für Onkologische Rehabilitation – UKF Reha gGmbH, Freiburg, Germany

26. Abteilung für Medizinische Psychologie und Medizinische Soziologie, Universitätsklinikum Leipzig, Leipzig, Germany

27. Gynäkologie & Geburtshilfe in Frauenfeld, Spital Thurgau AG, Frauenfeld, Switzerland

28. Privatklinik Döbling, Wien, Austria

29. Privatklinik Graz Ragnitz, Graz, Austria

30. Cancer Center, Sciensano, Brüssel, Belgium

31. Kleijnen Systematic Reviews Ltd, York, United Kingdom

32. Deutsche Krebsgesellschaft, Berlin, Germany

33. AWMF-Institut für Medizinisches Wissensmanagement, Marburg, Germany

34. Leitlinienprogramm Onkologie, Deutsche Krebsgesellschaft, Berlin, Germany

Abstract

Abstract Aims Annual opportunistic screening for cervical carcinoma has been carried out in Germany since 1971. The creation of this S3 guideline meets an important need, outlined in the National Cancer Plan, with regard to screening for cervical cancer, as the guideline aims to provide important information and support for planned organized screening for cervical cancer in Germany. Methods With the financial support of German Cancer Aid, 21 professional societies developed evidence-based statements and recommendations (classified using the GRADE system) for the screening, management and treatment of precancerous conditions of the cervix. Two independent scientific institutes compiled systematic reviews for this guideline. Recommendations The first part of this short summary presents the pathological basis and considers various questions related to screening for cervical cancer. As also reported in earlier reviews, the meta-analysis by Kleijnen Systematic Reviews showed that HPV-based screening offers better protection against invasive cervical cancer compared to cytology-based screening. The authors of this guideline therefore recommend – in accordance with the guideline of the Joint National Committee of Germany (Gemeinsamer Bundesauschuss, G-BA) – that women aged 35 and above should be examined at regular intervals (at least every 3 years) and undergo HPV-based screening. Co-testing can also be carried out. Women between the ages of 20 and 35 should have cytological screening every 2 years.

Publisher

Georg Thieme Verlag KG

Subject

Maternity and Midwifery,Obstetrics and Gynaecology

Link

http://www.thieme-connect.de/products/ejournals/pdf/10.1055/a-0818-5440.pdf

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of the Corona Pandemic on Cervical Cancer Screening Assessment;In Vivo;2024

2. Evaluations of the 2019 Annual Statistics Under the Cervical Cytology Quality Assurance Agreement;Geburtshilfe und Frauenheilkunde;2023-09-22

3. Standardized Procedures for Patients with Dysplasia and Other Diseases of the Cervix, Vulva, and Vagina at a Certified Dysplasia Unit Prior to the Introduction of the Organized Cervical Cancer Screening Program;Geburtshilfe und Frauenheilkunde;2023-08

4. Evaluation of the clinical performance of OncoPredict HPV® SCR assay within the VALGENT‐2 framework;Journal of Medical Virology;2022-12-27

5. COVID-19 can lead to rapid progression of cervical intraepithelial neoplasia by dysregulating the immune system: A hypothesis;Journal of Reproductive Immunology;2022-12